Isosorbide Mononitrate Tablets

Isosorbide mononitrate (ISMN) is the main biologically active metabolite of isosorbide dinitrate. Like other organic nitrates, its main pharmacological action is to relax vascular smooth muscle. ISMN releases nitric oxide (NO), which is the same as endothelial relaxing factor, activating guanylate cyclase, increasing cyclic guanosine monophosphate (cGMP) in smooth muscle cells, thereby relaxing vascular smooth muscle, dilating peripheral arteries and veins, and having a stronger dilating effect on veins. Venous dilation causes blood to remain in the periphery, reducing the amount of blood returning to the heart, and reducing left ventricular end-diastolic pressure and pulmonary capillary wedge pressure (preload). Arterial dilation reduces peripheral vascular resistance, systolic arterial pressure, and mean arterial pressure (afterload). Coronary artery dilation increases coronary perfusion. The overall effect is to reduce myocardial oxygen consumption, increase oxygen supply, and relieve angina pectoris. No carcinogenic and mutagenic phenomena were observed in animal experiments.

The chemical name of this product is: 1,4∶3,6-dianhydro-D-sorbitol-5-mononitrate. Molecular formula: C6H9NO6 Molecular weight: 191.14

White or off-white tablets.

It is used for long-term treatment of coronary heart disease, prevention of vasospastic and mixed angina pectoris, and is also suitable for treatment after myocardial infarction and long-term treatment of chronic heart failure.

Oral administration: 10-20 mg at a time, 3 times a day, or as directed by a doctor.

Nitrate-induced vasodilatory headache may occur in the early stage of medication, but the symptoms usually disappear after taking it for several days. Facial flushing, dizziness, orthostatic hypotension and reflex tachycardia may also occur. Occasionally, blood pressure is significantly reduced, bradycardia, angina pectoris is aggravated and syncope may occur.

Acute circulatory failure (shock, circulatory collapse); severe hypotension (systolic blood pressure 90 mmHg); acute myocardial infarction with low filling pressures (unless under continuous hemodynamic monitoring); hypertrophic obstructive cardiomyopathy; constrictive pericarditis or cardiac tamponade; severe anaemia; glaucoma; increased intracranial pressure; allergy to nitro compounds.

Precautions for children: Safety and effectiveness for children have not been established. Precautions for pregnancy and lactation: No adequate and strictly controlled experimental studies have been conducted on pregnant women. Reproductive studies on mice and rabbits have shown that isosorbide mononitrate is not found to be toxic to the embryo at maternal toxic doses. Because animal experiments cannot always predict human reactions, pregnant women can only take this product when necessary and under strict medical supervision. It is not known whether isosorbide mononitrate is excreted into breast milk, so it should be used with caution in lactating women. Precautions for the elderly: Elderly patients may be more sensitive to this type of drug and are more likely to experience reactions such as dizziness.

Combination with other vasodilators, calcium antagonists, beta-receptor blockers, antihypertensive drugs, tricyclic antidepressants and alcohol can enhance the blood pressure lowering effect of this class of drugs.

Keep away from light, sealed and stored in a dry place.

20mg*20s

36 months